PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Tohru Funahashi Selected Research
Adiponectin
05/2008
Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha.
04/2008
Prognostic value of adiponectin for cardiovascular disease and mortality.
04/2008
Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome.
02/2008
Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis.
01/2008
Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: The Korean atherosclerosis study (KAS) A 42-month prospective study.
01/2008
Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease.
10/2007
Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease.
09/2007
Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction.
09/2007
Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice.
07/2007
A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects.
04/2007
The genes influencing adiponectin levels also influence risk factors for metabolic syndrome and type 2 diabetes.
12/2006
Adiponectin and renal function, and implication as a risk of cardiovascular disease.
10/2006
Adiponectin and inflammatory markers in peripheral arterial occlusive disease.
09/2006
Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease.
09/2006
Effect of adiponectin on murine colitis induced by dextran sulfate sodium.
06/2006
Adiponectin replenishment ameliorates obesity-related hypertension.
03/2006
Adiponectin: a key adipocytokine in metabolic syndrome.
12/2005
Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
10/2005
Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.
09/2005
Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism.
07/2005
Resting metabolic rate is an important predictor of serum adiponectin concentrations: potential implications for obesity-related disorders.
04/2005
High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse.
01/2005
Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma.
01/2005
Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function.
01/2005
Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease--a follow-up study.
11/2004
Adiponectin as a biomarker of the metabolic syndrome.
07/2004
Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling.
07/2004
Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus.
04/2004
Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease.
01/2004
Adiponectin and metabolic syndrome.
12/2003
Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin.
12/2003
Obesity, adiponectin and vascular inflammatory disease.
11/2003
Association of serum adiponectin levels with breast cancer risk.
08/2003
A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin.
06/2003
Disturbed secretion of mutant adiponectin associated with the metabolic syndrome.
05/2003
Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors.
04/2003
Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy.
01/2003
Decreased plasma adiponectin concentration in patients with essential hypertension.
11/2002
Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.
11/2002
Plasma adiponectin levels in overweight and obese Asians.
10/2002
Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis.
10/2002
Low plasma adiponectin concentrations do not predict weight gain in humans.
10/2002
Plasma adiponectin concentrations in children: relationships with obesity and insulinemia.
09/2002
Adiponectin in essential hypertension.
07/2002
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.
07/2002
[Adiponectin as a key molecule of the metabolic syndrome]
07/2002
Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome.
01/2002
Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.
Articles by Research Topic
Disease
11
Syndrome
04/2008 - 07/2002
8
Obesity
03/2007 - 04/2002
6
Coronary Artery Disease (Coronary Atherosclerosis)
01/2008 - 04/2002
5
Atherosclerosis (Atheroma)
02/2008 - 11/2002
4
Insulin Resistance
07/2007 - 07/2002
4
Hypertension (High Blood Pressure)
06/2006 - 09/2002
3
Lipodystrophy
06/2004 - 04/2003
2
Fibrosis (Cirrhosis)
05/2008 - 09/2007
2
Cardiovascular Diseases (Cardiovascular Disease)
04/2008 - 12/2006
2
Breast Neoplasms (Breast Cancer)
03/2006 - 11/2003
2
Overweight
12/2005 - 11/2002
2
Nephrotic Syndrome (Syndrome, Nephrotic)
04/2005 - 05/2003
2
Chronic Kidney Failure (Chronic Renal Failure)
01/2005 - 01/2002
1
Obstructive Sleep Apnea
04/2008
1
Albuminuria
09/2007
1
Myocardial Infarction
09/2007
1
Anoxia (Hypoxia)
10/2006
1
Arterial Occlusive Diseases (Arterial Occlusive Disease)
10/2006
1
Colitis
09/2006
1
Reperfusion Injury
10/2005
1
Myocardial Ischemia (Ischemic Heart Diseases)
10/2005
1
Heart Failure
09/2005
1
Kidney Diseases (Kidney Disease)
01/2005
1
Ischemia
07/2004
1
Inflammation
07/2004
1
Gestational Diabetes (Gestational Diabetes Mellitus)
07/2004
1
Arteriosclerosis
03/2004
1
Liver Cirrhosis (Hepatic Cirrhosis)
12/2003
1
Cushing Syndrome
10/2003
1
Carcinoid Tumor (Carcinoid)
10/2003
1
Pathologic Constriction (Stenosis)
10/2002
1
Weight Gain
10/2002
Drug/Important Bio-Agent (IBA)
48
Adiponectin
IBA
05/2008 - 01/2002
3
Glucose (Dextrose)
FDA Link
Generic
11/2007 - 09/2005
2
Insulin (Novolin)
FDA Link
03/2008 - 07/2004
2
C-Reactive Protein
IBA
01/2005 - 03/2004
2
Adipokines
IBA
07/2003 - 01/2003
1
Angiotensin II
IBA
05/2008
1
PPAR alpha
IBA
05/2008
1
Ligands
IBA
02/2008
1
Resistin
IBA
01/2008
1
Pravastatin (Pravachol)
FDA Link
Generic
10/2007
1
secretogranin III
IBA
03/2007
1
Neuropeptides
IBA
03/2007
1
Nicotinamide Phosphoribosyltransferase
IBA
10/2006
1
Dextran Sulfate
IBA
09/2006
1
Leptin Receptors
IBA
03/2006
1
Messenger RNA (mRNA)
IBA
03/2006
1
Leptin
IBA
03/2006
1
Plasminogen Activators (Plasminogen Activator)
IBA
12/2005
1
Glycerol Kinase
IBA
08/2005
1
pioglitazone (Actos)
FDA Link
07/2005
1
rosiglitazone (Avandia)
FDA Link
06/2004
1
Carbon Tetrachloride (Tetrachloromethane)
IBA
12/2003
1
Adrenocorticotropic Hormone (ACTH)
FDA Link
10/2003
1
Apolipoproteins
IBA
11/2002
1
Hormones
IBA
11/2002
1
heparin-binding EGF-like growth factor (HB-EGF)
IBA
04/2002
Therapy/Procedure
2
Highly Active Antiretroviral Therapy (HAART)
06/2004 - 04/2003